Skip to main content

Table 2 Atrial fibrillation clinical management according to patient clusters

From: Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

 

Cluster 1

Cluster 2

Cluster 3

P

Antithrombotic treatment

 Any antiplatelet, n (%) 9356

708 (19.5)

304 (11.0)

812 (27.5)

< .001

 Any OAC, n (%) 9359

3143 (86.5)

2306 (83.2)

2563 (86.7)

< .001

 Any VKA, n (%) 9358

1833 (50.5)

1163 (42.0)

1639 (55.5)

< .001

 Any NOAC, n (%) 9354

1314 (36.2)

1145 (41.3)

925 (31.3)

< .001

 Antithrombotic pattern, n (%)

   

< .001

  No antithrombotic

217 (6.0)

318 (11.5)

142 (4.8)

 

  Only antiplatelet

273 (7.5)

147 (5.3)

250 (8.5)

 

  Only VKA

1524 (42.0)

1059 (38.2)

1228 (41.6)

 

  Only NOAC

1182 (32.6)

1089 (39.3)

773 (26.2)

 

  Antiplatelet + OAC

435 (12.0)

157 (5.7)

562 (19.0)

 

Primary management (before admission)

   

< .001

 Primary management strategy, n (%) 7753

   

< .001

  Rate control

1371 (45.3)

802 (36.5)

1317 (52.0)

 

  Rhythm control

1203 (39.8)

1083 (49.3)

852 (33.7)

 

  Observation

452 (14.9)

311 (14.2)

362 (14.3)

 

 Primary ECV, n (%) 7350

693 (24.1)

604 (28.5)

476 (20.2)

< .001

 Primary PCV, n (%) 7281

730 (25.6)

629 (29.9)

621 (26.6)

.003

 Primary catheter ablation, n (%) 7531

171 (5.8)

181 (8.4)

108 (4.4)

< .001

Management during admission/consultation

   

<.001

 Intervention planned/performed, n (%) 9363

1285 (34.6)

1150 (41.5)

984 (33.3)

<.001

 ECV, n (%) 3392

566 (45.0)

628 (54.6)

379 (38.5)

< .001

 PCV, n (%) 3392

304 (24.2)

204 (17.7)

245 (24.9)

< .001

 Catheter ablation, n (%) 3392

176 (14.0)

261 (22.7)

100 (10.2)

< .001

 Management strategy at discharge, n (%)

   

< .001

  Rate control

1724 (47.5)

984 (35.5)

1522 (51.7)

 

  Rhythm control

1365 (37.6)

1333 (48.1)

981 (33.3)

 

  Observation

537 (14.8)

452 (16.3)

442 (15.0)

 

 ABC pathway adherence, n (%)

666 (30.8)

655 (34.5)

431 (26.2)

< .001

  1. Legend: ECV electrical cardioversion, NOAC non-vitamin K antagonist oral anticoagulant, OAC oral anticoagulant, PCV pharmacological cardioversion, VKA vitamin K antagonist